CClinicalTrials.gg
Active, not recruitingNCT05228067STIMUpdated Mar 30, 2025

Enhancing Brain Health by TDCS in Persons with Overweight and Obesity

An interventional study of anodal transcranial direct current stimulation and cathodal transcranial direct current stimulation in Insulin Resistance, Obesity and Diabetes Type 2, sponsored by University Hospital Tuebingen. Active, not recruiting at 1 site in Germany. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

Disturbances in the hypothalamus communication pathways with other regions in the brain and the periphery may represent a potential link between metabolic and cognitive health. The current project evaluates whether enhancing synaptic plasticity of this pathway can improve weight management, insulin sensitivity, and cognitive functions. In recent studies, we were able to show that the human brain is sensitive to insulin with favorable effects on peripheral metabolism and cognition. These brain regions encompass the hypothalamus and its connections to the striatum and prefrontal cortex. We want to investigate whether it is possible to enhance neuroplasticity of insulin-responsive brain regions to suppress the weight gain trajectory and improve dopamine-dependent cognitive functions in people with a high risk to develop type 2 diabetes. For this purpose, neuroimaging tools using high-definition transcranial direct current stimulation (HD-tDCS) and magnetic resonance imaging (MRI) will be implemented to assess synaptic plasticity of a neural network essential for metabolic and cognitive health.

Read the detailed description

The overarching aim of the study is to investigate the possibility to enhance neuroplasticity of the hypothalamus network to improve metabolism and dopamine-dependent cognitive functions.

Specific objectives

  • Specifically, it is the first aim to study the predictive value of white matter microstructure (fiber tracts structurally connecting the target network) for tDCS-intervention response and to investigate tDCS-induced neuroplasticity changes of the hypothalamus brain network using functional magnetic resonance imaging (fMRI).
  • It is the second aim of this study to deepen our understanding of brain structure and function of the target network, which is known to rely on the neurotransmitter dopamine for its communication. Hence, we will use dopamine-dependent cognitive and eating behavior assessments.

Participants will receive a thorough screening to obtain body composition by MRI, anthropometric measures, fasting glucose and insulin, indirect calorimetry, and general cognitive functions. Thereafter, participants will participate in three measurement days (separated by approx. one week) to receive a 25 min tDCS stimulation targeting the hypothalamus network in a double-blind cluster-randomized. Participant are randomized on three conditions: sham stimulation, anodal and cathodal stimulation. During the non-invasive brain stimulation, participants will perform a stop-signal task. On each measurement day, structural and functional MRI measurements are performed before and after stimulation. Dopamine-dependent behavior (i.e. reward task) will be assessed during fMRI measurement. Subsequently, participants will receive a breakfast buffet. The caloric intake from fat, carbohydrates and protein will be documented. Subjective feeling of hunger and food craving will be assessed using a visual analogue scale before stimulation, directly after stimulation and after breakfast. Food pictures will be rated on a laptop for taste and healthiness.

02

Conditions studied

  • Insulin Resistance
  • Obesity
  • Diabetes Type 2

Keywords

  • tDCS
  • MRI
  • hypothalamus
  • functional connectivity
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's planned enrollment of 40 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 476 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Written consent to participate in the study
  • Written consent to be informed about incidental findings

Overweight and obese participants:

  • Body mass index (BMI) between 28 and 39.5 kg/m2
  • Age between 20 to 65 years of age
  • Waist circumference > 80 cm for women, > 94 cm for men

Sex and age matched normal weight individuals:

  • Body mass index (BMI) between 19.5 and 24.5 kg/m2
  • Age between 20 to 65 years of age

Exclusion criteria

Exclusion Criteria:

  • Insufficient knowledge of the German language
  • Persons who cannot legally give consent
  • Pregnancy or lactation
  • History of severe mental or somatic disorders including neurological diseases (incl. Epileptic seizures)
  • Taking psychotropic drugs
  • Previous bariatric surgery
  • Acute infection within the last 4 weeks
  • Hemoglobin values less than 12g/dl for women, less than 14 g/dl for men
  • Current participation in a lifestyle intervention study or a pharmaceutical study
  • Contradictions to a MRI measurement (e.g. metal implants)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Anodal stimulation

    Anodal tDCS of the hypothalamus network

    Device: anodal transcranial direct current stimulation

  • Active comparator
    Cathodal stimulation

    Cathodal tDCS of the hypothalamus network

    Device: cathodal transcranial direct current stimulation

  • Sham comparator
    Sham stimulation

    Sham tDCS of the hypothalamus network

    Device: sham transcranial direct current stimulation

Interventions

  • Deviceanodal transcranial direct current stimulation

    anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.

    Also known as: anodal tDCS, excitatory tDCS

  • Devicecathodal transcranial direct current stimulation

    anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.

    Also known as: cathodal tDCS, inhibitory tDCS

  • Devicesham transcranial direct current stimulation

    Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)

    Also known as: sham tDCS

06

What researchers measure

Primary outcomes

  1. Change in neuroplasticity

    Fractional anisotropy (FA) of the target network

    Time frame: 20 minutes directly before and after tDCS stimulation

  2. Change in functional connectivity

    Resting state functional connectivity of the target network

    Time frame: 20 minutes directly before and after tDCS stimulation

  3. Change in eating behavior

    Caloric intake (kcal), Free-choice, ad libitum food intake from a standardized breakfast buffet. The caloric intake from fat, carbohydrates and protein will be documented

    Time frame: 1 hour after tDCS stimulation

  4. Change in dopamine-dependent cognitive function

    Changes in dopamine-dependent cognitive function and reward sensitivity measured by a reward-based decision-making task

    Time frame: 20 minutes after tDCS stimulation

Secondary outcomes

  1. Change in subjective ratings

    Change in subjective ratings will be assessed using a visual analogue scale for hunger and subjective feeling of craving using a questionnaire (Food craving questionnaire). Visual analogue scale using a range from 0 to 10 cm, higher values indicating more hunger. Food craving questionnaire based on ordinal scale from 1 to 5, higher values indicating more food craving

    Time frame: 5 minutes before tDCS stimulation, 5 minutes after tDCS stimulation and 5 minutes after buffet

  2. Performance during stop-signal task

    Outcome measures cover direction errors, proportion of successful stops, reaction time on Go trials, and stop signal reaction time (SSRT)

    Time frame: task is performed during 25-minutes tDCS stimulation

  3. Tastiness and healthiness rating of food stimuli

    Using a computer based task, participants rate food pictures of low caloric and high caloric foods and snacks on a 5-point scale based on subjective tastiness and healthiness

    Time frame: task is performed immediately after buffet

  4. Food choice

    Using a computer based task, participants have to choose food items they preferred to eat compared to a reference food on a 5-point choice scale. The reference (or "neutral") food item is individually determined based the health and taste rating \[Scale: 1= not tasty/ not healthy up to 5= very tasty/ very healthy\]

    Time frame: task is performed immediately after buffet

07

Study locations

1 site
  • University Clinic Tübingen
    Tübingen, 72076, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05228067
Lead sponsor
University Hospital Tuebingen
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Nov 8, 2021
Primary completion
Dec 30, 2024
Completion
Dec 31, 2025 (estimated)
Last update
Mar 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion